Investment
Features
FeesSafety
Academy
More
Pluang+

Compare CVS Health Corp (CVS) vs Rockwell Automation (ROK) Price & Performance

CVS Health CorpTrade
Rockwell AutomationTrade

Price performance (Past 24H)

Key statistics

CVS Health Corp vs Rockwell Automation — how do they compare? CVS Health Corp trades at $86.82 (market cap $112.49B), while Rockwell Automation trades at $438.29 (market cap $49.07B). The key difference: CVS Health Corp is far larger — about 2.3× Rockwell Automation's market cap, and CVS Health Corp pays the higher dividend (3.02%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Rockwell Automation for 74 Days on average.

CVSROK
Market Cap
$112.49B$49.07B
Volume
8,467,392783,067
Sector
HealthIndustrials
52-Week High
$110.60$495.08
52-Week Low
$70.08$333.75
Typical Hold Time
83 Days74 Days
Enterprise Value
$174.83B$52.21B
Dividend Yield
3.02%1.25%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

CVS Health Corp

CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.

The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.

Rockwell Automation

Rockwell Automation (ROK) trades at $434.14, down 3.68% on the day, with a bullish technical signal from moving averages. The company has beaten earnings estimates for the last three quarters, with Q3 2026 results pending. Revenue for 2025 was $8.34 billion, with a net income margin of 13.38%. Recent news highlights its leadership in industrial automation and digital transformation, including partnerships in AI-enabled cyber defense.

The outlook is supported by strong profitability and analyst consensus, but high valuation multiples and competitive pressures pose risks. The consensus price target of $489.89 suggests potential upside, though investors should monitor earnings sustainability and macroeconomic factors affecting industrial demand.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CVS

No sentiment data available yet.

ROK
0% Buy100% Sell
Avg holding period · 74 Days

Top news

Latest headlines on both assets

About CVS Health Corp

Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.

Read more on CVS →

About Rockwell Automation

Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.

Read more on ROK →